Jonathan Evan Shoag on Muck Rack

Jonathan Evan Shoag

As seen in: European Urology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jonathan Evan

Contact Jonathan Evan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Re: Kitamura et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection (JCOG1019). Eur Urol 2026. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008

|
By Spyridon P. Basourakos, Jonathan Evan Shoag, Adam C. Calaway
| European Urology Verified
Get full text access Log in, subscribe or purchase for full access. References 1. Kitamura H, Tsukamoto T, Kakehi Y, et al. Active surveillance versus intravesical Bacillus Calmette-Guérin for high-grade T1 bladder cancer with negative second transurethral resection: the randomized noninferiority phase 3 JCOG1019 trial. Eur Urol 2026. In press. https://doi.org/10.1016/j.eururo.2026.01.008. 2. Shore, N.D. ∙ Powles, T.B. ∙ Bedke, J. ...
Open in Who Shared Issue with article?

Re: MRI-guided Focused Ultrasound Focal Therapy for Patients with Intermediate-risk Prostate Cancer: A Phase 2b, Multicentre Study

|
By William Hall, Jonathan Evan Shoag, Daniel E. Spratt
| European Urology Verified
Re: Bernadett Szabados, Mark Kockx, Zoe June Assaf, et al. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. Eur Urol 2022;82:212–22
Open in Who Shared Issue with article?

Re: Safety and Efficacy of Virtual Prostatectomy with Single-dose Radiotherapy in Patients with Intermediate-risk Prostate Cancer: Results from the PROSINT Phase 2 Randomized Clinical Trial

|
By Jonathan Evan Shoag, Alexander Hill, Yonsei College, Jae Hug Jung
| European Urology Verified
Jonathan Evan Shoag Jonathan Evan Shoag Correspondence Corresponding author. University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, US.
Open in Who Shared Issue with article?
See all 4 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified